Iridex Launches Next Gen PASCAL® Laser with MicroPulse® in Full U.S. Market > IRIDEX



The new Iridex PASCAL combines industry-leading speed and precision pattern scanning, Endpoint Management Technology, Pattern Scanning Laser Trabeculoplasty, and now, MicroPulse Technology, in an integrated laser platform using half the footprint of its predecessor.

MOUNTAIN VIEW, Calif., April 19, 2023 -- Iridex Corporation (Nasdaq: IRIX), a provider of innovative laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the full market launch of the next generation Iridex PASCAL. The new PASCAL platform, first offered in limited release beginning late 2022, provides an advanced technology package combining fast and precise pattern scanning capabilities, Endpoint Management Technology, Pattern Scanning Laser Trabeculoplasty, and MicroPulse® Technology in a smaller, ergonomically-optimized integrated laser platform.

“Our full U.S. launch of the next generation PASCAL platform brings a new standard to the scanning laser market, with its premium performance, throughput-focused user interface and expanded treatment capabilities delivered in about half the space,“ said David I. Bruce, President and CEO of Iridex. “By integrating the traditional electronics box into the treatment table and adding our clinically proven MicroPulse Technology, we now offer physicians a broader choice of premium treatment modalities in a compact, ergonomic system to address a wide array of patient needs.”

The Iridex PASCAL offers three tissue-sparing technology options:

  • MicroPulse Mode is Iridex’s proprietary and patented technology. It chops a continuous-wave laser beam into sequences of short, repetitive, low-energy pulses separated by longer rest periods which allows the tissue to cool between laser pulses. An extensive bibliography of clinical research demonstrates its safety and efficacy for the treatment of retinal diseases and glaucoma.
  • Endpoint Management (EpM) is a pattern subthreshold retinal laser therapy that uses a unique algorithm to control laser power and pulse duration, optimizing the therapeutic effect.
  • Pattern Scanning Laser Trabeculoplasty provides a rapid and precise computer-guided treatment that applies a sequence of patterns onto the trabecular meshwork to reduce intraocular pressure.

“Having all three of these advanced treatment modalities in one platform widens my clinical reach while freeing up valuable practice space,” said Dr. Victor H Gonzalez of Gulf Coast Eye Institute in McAllen, Texas. “High performance, compact solutions like these broaden the resources at our disposal, allowing us to deliver outstanding, individualized care to more patients with glaucoma and retinal disease.”

The new Iridex Pattern Scanning Laser (PASCAL) offers a smaller physical footprint, intuitive touchscreen controls, and ADA-compliant wheelchair accessibility. The PASCAL product line continues to efficiently deliver large laser patterns reducing treatment time and patient discomfort during treatment. The innovative four-fiber beam design improves depth of focus during treatment, ensuring consistent energy delivery across multiple tissue elevations and in the far periphery of the retina. Intuitive user interface provides easy access to a wide variety of pattern variations, and the auto advance feature delivers sequential patterns without taking physician’s eyes away from oculars. The Iridex PASCAL is currently available in 577 nm (yellow) or 532 nm (green) models.

About Iridex

Iridex is a worldwide leader in developing innovative and versatile laser-based medical systems, delivery devices, and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven therapy for targeted sight-threatening eye conditions. Iridex’s products treat glaucoma, diabetic macular edema, and other retinal diseases. Iridex products are sold in the United States and Germany through a direct sales force and in more than 100 countries through a network of independent distributors. For more information, visit

Iridex Media Contact

Jamie Hall

Posted in: News
Actions: E-mail | Permalink |